3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Pancreatic Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Rectal Neoplasms
6
Colorectal Neoplasms
6
Breast Neoplasms
6
Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Stomach Neoplasms
3
Oligodendroglioma
3
Mouth Neoplasms
3
Lung Neoplasms
3
Glioma
3
Esophageal Neoplasms
3
Astrocytoma
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Meningioma
2
Melanoma
2
Gliosarcoma
2
Glioma, Subependymal
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Adenocarcinoma Of Esophagus
2
Xerostomia
1
Interventions
Ipilimumab
4
tremelimumab
1
tilsotolimod
1
durvalumab
1
Vemurafenib
1
Vaccination
1
Surgical Procedures, Operative
1
Nivolumab
1
Melphalan
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Surgical Procedures, Operative
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled